BigHat is an AI-native biotechnology company designing and developing next-generation therapeutics, powered by a proprietary AI platform and gold-standard data
@BigHatBio’s CSO, Stefan Weigand, will be featured on the AI for Sequence Design panel at #GATC2026 on Wed, November 18th, at 11:15am (PT). Dr. Weigand will discuss BigHat’s contribution to recent advances in AI- guided antibody design, our demonstration of translation to the clinic with BHB810 and BHB299, and how we have overcome technical bottlenecks with a platform that seamlessly integrates an automated wet lab with the best of ML technologies.
Learn more or register at GATC website: https://t.co/zpTdtcXorU
Since day one, @BigHatBio has been a partner of choice to pharma for leveraging our lab in a loop to accelerate and overcome therapeutic challenges. More recently, we have worked with a broader set of partners to generate valuable training data sets, customize models, and benchmark LLM performance.
Learn more about our platform, pipeline, and partnering efforts from our CEO, @peytongreenside, on the AI drug discovery panel at the @UBS Conference on Tuesday, November 17 at 2pm or schedule a meeting with her and our CBO, @liz_schwarzbach at or adjacent to the @Jefferies Healthcare conference.
Today @BigHatBio and @AnthropicAI released a joint demonstration of how challenging antibody engineering problems can be accelerated under a new paradigm powering frontier AI with a fully integrated and agent-accessible rapid-feedback wet lab. By reimagining the traditional antibody engineering framework focused on sequence optimization, our joint work shows that faster and better outcomes along with new scientific insights come as human-agent teams reason over the full experimental process alongside each produced antibody design.
BigHat has built an Agentic Lab Control Harness that brings every computational and experimental workflow at BigHat into the same control plane for today’s best frontier intelligence. We’re proud to be selected as an initial antibody therapeutic partner by Anthropic to reimagine what is possible in drug creation at today’s technology frontier.
Read our technical report: https://t.co/QkwZeolkaw
BigHat’s blog post: https://t.co/bkBfuANvx2
Anthropic’s blog post: https://t.co/bTcfPGnKSF
@BigHatBio is hiring! We’re rapidly expanding our platform and team in the SF Bay Area. We have multiple roles in machine learning, platform production, antibody engineering, and corporate operations!
Check out https://t.co/90nZOfjvSu for opportunities to do BIG things!
Hear from BigHat’s leadership on two coasts tomorrow, October 22nd!
📍 AWS Hackathon Panel: The Next Frontier in AI for Life Sciences in SF
Our VP of Platform, Charbel Eid, will take the stage with Khalil Kaddoura of Optagon Labs, Krish W. Ramadurai of AIX Ventures, Nicholas Larus-Stone of Benchling and Bits in Bio, and Alfredo Andere of LatchBio to discuss how models, agents, and better data are changing what’s possible in drug development. Stick around for pitches from the Self-Accelerating AI for Drug Development Hackathon teams!
🗓️ October 22 | 5:00 to 7:00 PM | AWS Builder Loft, 525 Market St, 2nd Floor
Save your spot: https://t.co/BSkWWtuVZO
📍 NY Biotech Industry Partnership Forum
Our Chief Business Officer, Elizabeth Schwarzbach, will discuss how to build bridges and impactful partnerships between academia and industry to drive innovation and impact, hosted by The Research Foundation for SUNY.
🗓️ October 22 | SUNY Global Center, 116 East 55th Street
Save your spot:
https://t.co/IpMNWNFG48
We welcome Michelle Gaus, Brendan Mullaney, and Glori Marie Roman!
Glori joins BigHat’s as Scientist I, Molecular Biology. Glori Roman, PhD, is a chemical biologist with specialized expertise in antibody engineering and protein characterization. She obtained her BS in Chemistry from the @uprm and then moved to Nebraska to pursue her graduate degree at the @UNLincoln, where she focused on engineering diagnostic antibodies and biosensors using cutting-edge techniques such as non-canonical amino acid incorporation. At 23andMe, she made significant contributions to optimizing and developing assays for the selection of antibodies for the company’s pipeline, as well as advancements in bispecific antibody engineering and development.
Brendan Mullaney joins as Director, Scientific Software Product. Brendan is a scientist and software product manager with a background in clinical genomics, cancer diagnostics, scientific software development and neuroscience. He earned his B.A. in Neuroscience from @JohnsHopkins, his Ph.D. in Neuroscience from @UCSF and completed a postdoc at @UCBerkeley. Brendan previously held leadership roles in software product management at @GrailBio and @Invitae.
Michelle joins as BigHat's new Senior Manager of People Operations. Michelle is an HR professional with over nine years of experience in the pharmaceutical industry, specializing in performance management, employee relations, and HR operations. With a data-driven approach and a strong focus on fostering a high-performance culture, Michelle works to enhance productivity and align HR strategies with business goals. She is passionate about continuous professional development and values creating workspaces where all employees can thrive. Michelle holds a Bachelor’s degree in Marketing from @MarquetteU and is a certified SHRM-CP.
Welcome to the team, Brendan, Michelle and Glori!
https://t.co/rfrtOrK7fe
We’re thrilled to share that @ryan_henrici, our VP of Discovery Medicine, has been selected as a recipient of @penn_state's 2025 Alumni Achievement Award!
This prestigious honor celebrates Ryan’s exceptional contributions to science and medicine—from his early academic achievements to his transformative work here at BigHat Biosciences, where he’s advancing the frontier of AI-driven antibody discovery and development.
Ryan’s leadership and passion continue to inspire us as we push the boundaries of therapeutic innovation. We’re proud to have him on the BigHat team.
We are excited to share an important leadership update at BigHat Biosciences. @peytongreenside has stepped into the role of CEO, bringing deep scientific expertise, strategic vision, and a strong commitment to our mission to develop better biologics through ML-guided design.
We also want to express our sincere gratitude to @MarkDePristo – his leadership and partnership have been instrumental in shaping BigHat into what it is today. We look forward to his continued support as an advisor in this next chapter.
Read more here: https://t.co/y1RsCIveJP
BigHat’s machine learning team is excited to share its latest paper, in collaboration with the Gordon Wilson Lab at @nyuniversity, “Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences,” which was accepted for publication at the prestigious International Conference on Learning Representations (@iclr_conf).
This work aims to model the natural antibody affinity maturation process to guide Bayesian optimization of synthetic antibodies. This is accomplished by building large language models of putative clonal families of antibody sequences and then combining these models with BigHat-generated lab data to design mutations which improve both binding and stability.
This work builds on the contributions of @AlanNawzadAmin, @gruver_nate, @KuangYilun, and Lily Le from @andrewgwils's lab, as well as @peytongreenside, Hunter Elliott, Aniruddh Raghu, and Calvin McCarter at BigHat.
Access to the paper can be found at https://t.co/AjPUQQWRt5
Hunter Elliott (Sr. Director, Machine Learning) will give his invited talk “Generative and Predictive Machine Learning for Iterative Multi-Objective Therapeutic Antibody Optimization” at the Biologic Summit 2025 in San Diego on January 15, 2025.
In this talk, Hunter explores how BigHat's innovative Milliner™ platform seamlessly integrates predictive and generative models with high-throughput wet labs to address complex protein engineering challenges in antibody therapeutics. He will share several case studies showcasing novel predictive and generative ML methods deployed on Milliner™ to solve real-world therapeutic engineering problems.
https://t.co/g2OPUk1APb
BigHat is excited to kick off 2025 with a productive @jpmorgan Healthcare Conference 2025!
On Tuesday, January 14, 2025 our CEO, @MarkDePristo, will speak on the Next in Tech Bio | Computational Strategies for Drug Discovery panel (⏰ 7:00PM @ 📍 Benchling) and CBO, Liz Schwarzbach, is thrilled to be hosting an Executive Roundtable at @WuXi_AppTec's #WuXiGlobalForum (⏰ 1:30PM @📍Continental Ballrooms (4-6) | Hilton Union Square)
https://t.co/Lb01a9t4g6
We can’t wait to see you there! 👋
This holiday we’re thankful for the expertise and hard work of our talented employees, advisors, partners, board of directors and investors. Please know we appreciate each and every one of your contributions. Thank you for being a BigHatter!
BigHat Biosciences will be completely shut down over the holidays, starting December 23rd, in order to foster a healthy work environment. We will reopen on December 30th, 2024, fully committed to advancing our mission of developing better biologics faster through ML-guided design.
Wishing you a healthy and happy new year,
The BigHat Team
BigHat’s VP of Discovery Medicine, @ryan_henrici, will be giving his invited talk "Machine Learning-guided Design of Logic Gated and Avidity-driven T Cell Engagers for Solid Malignancies” at the @AntibodyEngIC Conference on December 17th at 11 AM PST in San Diego.
The talk will cover how machine learning supports efficient T cell engager (TCE) design to target co-expressed tumor antigens while sparing healthy tissues, even at high receptor densities. This approach integrates AI/ML with rapid wet-lab validation to advance safer and more effective therapies for solid tumors.
Join the session to explore how data-driven methods are improving TCE development: https://t.co/upikEDx00V
In addition, Ryan shared his insights with AE&T last week into his journey from medical training to leading cutting-edge antibody engineering at BigHat, all fueled by a mission to create safer therapies.
To watch the full interview: https://t.co/sghbyCjuym
Hunter Elliott, BigHat’s Sr. Director of Machine Learning, as well as @AlanNawzadAmin, from the @andrewgwils lab at @nyuniversity, will be presenting a paper titled, “Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences” at the @NeurIPSConf 2024 AIDrugX workshop, in Vancouver from December 10-15
This work aims to model the natural antibody affinity maturation process to guide Bayesian optimization of synthetic antibodies. This is accomplished by building large language models of putative clonal families of antibody sequences and then combining these models with BigHat-generated lab data to design mutations which improve both binding and stability.
Read paper: https://t.co/umZcof37Pk
Conference: https://t.co/KJyPOWtjhR
Workshop: https://t.co/MY7bRDlx3l
We welcome Sebastian Ober, Fah Sathirapongsasuti and Nicholas Young.
Sebastian joins BigHat’s Machine Learning team as Senior Machine Learning Scientist I. Sebastian will focus on improving BigHat’s integration of multimodal experimental data in Bayesian Optimization for antibody design. Sebastian completed his PhD in the Machine Learning Group at @Cambridge_Uni , where he focused on representing uncertainty in deep learning and active learning. Prior to that, he completed his undergraduate and Masters degree in engineering, also at Cambridge. Before joining BigHat, Sebastian worked at @AstraZeneca and @SecondmindAI.
Fah Sathirapongsasuti joins as BigHat's new Senior Director of Data Science. Fah brings over a decade of biopharma experience, specializing in computational biology for target and drug discovery. At @23andMe's Therapeutics Division, Fah was a founding scientist and pioneered the use of human genetics for drug target identification and prioritization. He has also led bioinformatics and data science teams as Director of Bioinformatics, Genetic Medicine at @MedGenomeLabs and Director of Computational Biology at @AlloyTx, focusing on data organization and tool development for next-generation therapeutics. Fah holds a PhD in Biostatistics from @Harvard and BS/MS degrees in Mathematical and Computational Science/Computer Science from @Stanford.
Nicholas Young joins as Scientist I, to our External Programs. Nick will be performing and developing assays to support our internal and partnered programs. Nicholas is a chemical biologist with an interest in dissecting sequence-function landscapes of proteins. During his graduate work, he developed methods for the high-throughput screening and functional characterization of proteases, small molecules, and antibodies. He earned his PhD in Chemistry and Chemical Biology from the @UCSF, and a BS in Chemistry from the @penn_state. In addition, Nicholas previously worked as a Postbaccalaureate Fellow at the @NIMHgov and as a Protein Biochemistry Intern at Denali Therapeutics.
Welcome to the team, Nicholas, Fah and Sebastian!
https://t.co/rfrtOrK7fe